A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer-Reference-Cited by-同舟云学术

A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer

Published:2008-03-06 Issue:1 Volume:63 Page:109-115
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

LoConte Noelle K.,Thomas James P.,Alberti Dona,Heideman Jennifer,Binger Kimberly,Marnocha Rebecca,Utecht Kyle,Geiger Peter,Eickhoff Jens,Wilding George,Kolesar Jill

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-008-0719-5.pdf

Reference25 articles.

1. Aghajanian C, Soignet S, Dizon DS et al (2002) A phase 1 trial of the novel proteosome inhibitor PS314 in advanced solid tumor malignancies. Clin Cancer Res 8:2505–11

2. Adams J (2002) Preclinical and clinical evaluation of proteasome inhibitor bortezomib for the treatment of cancer. Curr Opin Chem Biol 6:493–500

3. An J, Sun Y, Fisher M et al (2004) Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 18:1699–704

4. Devoy A, Soane T, Welchman R et al (2005) The ubiquitin-proteasome system and cancer. Essays Biochem 41:187–203

5. DeWys WD, Bauer M, Colsky J et al (1977) Comparitive trial of adriamycin and 5-fluorouracil in advanced prostatic cancer-progress report, Cancer Treat Rep 61:325–328

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancer;Expert Opinion on Investigational Drugs;2019-01-28

2. Molecular mechanism of doxorubicin-induced cardiomyopathy – An update;European Journal of Pharmacology;2018-01

3. Melanoma;Angiogenesis-Based Dermatology;2017

4. pH/NIR Light-Controlled Multidrug Release via a Mussel-Inspired Nanocomposite Hydrogel for Chemo-Photothermal Cancer Therapy;Scientific Reports;2016-09

5. Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials;Journal of Clinical Oncology;2016-04-20